Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Needham & Company LLC reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report published on Friday morning,Benzinga reports. They ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The ...

For the quarter ended December 2024, Alnylam Pharmaceuticals (ALNY) reported revenue of $593.17 million, up 34.9% over the same period last year. EPS came in at $0.06, compared to -$1.10 in the ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

Scotiabank lowered the firm’s price target on Alnylam (ALNY) to $300 from $310 and keeps an Outperform rating on the shares. The firm is ...

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...